Skip to content

Clinical trials

Phase 3 Cognitive Dysfunction trials in Australia

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Cognitive Dysfunction Phase: Phase 3 Country / region: Australia Clear all

12 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20141
20161
20191
20202
20223
20254

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Active, not recruiting5
Recruiting4
Terminated3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Bristol-Myers Squibb2
Eli Lilly and Company2
Hoffmann-La Roche2
Donald Mabbott1
Eisai Co., Ltd.1
Eisai Inc.1
Garvan Institute of Medical Research1
TauRx Therapeutics Ltd1
The George Institute1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Cognitive Dysfunction12
Alzheimer Disease9
Dementia7
Brain Diseases2
Neurodegenerative Diseases2
Plaque, Amyloid2
Central Nervous System Diseases1
Cerebral Hemorrhage1
Cerebral Small Vessel Diseases1
Cerebrovascular Disorders1

Trials

Showing 1 to 12 of 12. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.